The estimated Net Worth of Tsveta Milanova is at least 658 千$ dollars as of 20 January 2024. Tsveta Milanova owns over 5,448 units of Agios Pharmaceuticals Inc stock worth over 658,092$ and over the last 2 years Tsveta sold AGIO stock worth over 0$.
Tsveta has made over 3 trades of the Agios Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Tsveta exercised 5,448 units of AGIO stock worth 241,401$ on 20 January 2024.
The largest trade Tsveta's ever made was exercising 8,475 units of Agios Pharmaceuticals Inc stock on 3 January 2024 worth over 375,527$. On average, Tsveta trades about 3,874 units every 41 days since 2023. As of 20 January 2024 Tsveta still owns at least 14,852 units of Agios Pharmaceuticals Inc stock.
You can see the complete history of Tsveta Milanova stock trades at the bottom of the page.
Tsveta's mailing address filed with the SEC is C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Over the last 11 years, insiders at Agios Pharmaceuticals Inc have traded over 77,887,085$ worth of Agios Pharmaceuticals Inc stock and bought 3,229,562 units worth 154,554,190$ . The most active insiders traders include Kevin P Starr、Robert Nelsen、John Maraganore. On average, Agios Pharmaceuticals Inc executives and independent directors trade stock every 9 days with the average trade being worth of 765,588$. The most recent stock trade was executed by Rahul D. Ballal on 11 August 2024, trading 2,302 units of AGIO stock currently worth 102,002$.
at agios, we are doing incredibly important and difficult work. we are trying to discover and develop breakthrough medicines, and we have a clear motivator — people with cancer and rare genetic diseases who are counting on us to be successful. we are a science-driven research organization. we have built a discovery platform upon our expertise in the fields of cellular metabolism and precision medicine across three major focus areas: cancer metabolism, rare genetic metabolic disorders and metabolic immuno-oncology. it takes people with a diversity of thought, skills, passions and backgrounds to get us from the first stages of understanding new biology and discovering drugs to our ultimate goal of getting these medicines to patients who are waiting for them. our connection to one another and our work and our commitment to our values enable us to potentially change the practice of medicine by by striving for excellence and doing things differently. we call this the "other side of possible
Agios Pharmaceuticals Inc executives and other stock owners filed with the SEC include: